Get to know our clinical trials
Clinical trial of nab-paclitaxel and gemcitabine with or without SBP-101 in patients with previously untreated metastatic pancreatic ductal adenocarcinoma
THE GOAL OF THE STUDY IS TO TEST WHETHER SBP-101 COMBINED WITH NAB-PACLITAXEL AND GEMCITABINE IS EFFECTIVE IN TREATING ADENOCARCINOMA. THE STUDY ALSO AIMS TO FIND OUT WHETHER SBP-101 COMBINED WITH NAB-PACLITAXEL AND GEMCITABINE IS SAFE (IF YOU OR OTHER PATIENTS HAVE SIDE EFFECTS) AND WELL TOLERATED (IF YOU OR OTHER PATIENTS TOLERATE THE SIDE EFFECTS) BY PATIENTS WITH ADENOCARCINOMA.
Technical Summary
- RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF NAB-PACLITAXEL AND GEMCITABINE WITH OR WITHOUT SBP-101 IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA OF THE PANCREAS
- Code EudraCT: 2021-005790-60
- Protocol number: CL-SBP-101-04
- Promoter: Panbela Therapeutics, Inc.
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.